EFTA00370849Set 9
2014-04-226p1,752w
make a run at
Allergan (AGN +21% after the close). And now Novartis & GSK have announced a major series of transactions:
creating new consumer-health venture (GSK 63.5% controlling interest ... Novartis agrees to buy GSK's oncology
unit for as much as $16B, Novartis to sell vaccines unit to Glaxo for $7.1B, Novartis to sell Animal Health unit ... venture
• Novartis to divest Animal Health to Lilly for $5.4B (NOVN VX +2.3%, GSK LN +5.3%, LLY no volume)
• Astrazeneca ADR's closed +8.8% yesterday on Sunday Times story
https://www.justice.gov/epstein/files/DataSet%209/EFTA00370849.pdf
EFTA01274387Set 10
2014-02-02330p153,621w
This information was unavailable-- 25.440 50371 20
GLAXO SMITHKLINE PLC ADR
Symbol. GSK Exchange. NYSE
EAI: $2,506 Cisrent yield: 4.41% 1,015.000 ---This information was unavailable ... GLAXO SMRHK UNE PLC ACE
Symbol: GSK Exchange: NYSE
EAI: 12,506 Current yield
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01274387.pdf
EFTA01103797Set 9
2013-09-2315p5,239w
fund that you can mention include Sweden, CIFF, KfW, Grand Challenges
Canada, GSK, Merck, Pfizer, IFC and J.P. Morgan
Suggested Talking Points — Meeting with Key Partners:
Following the conclusion ... global health goal. Sweden brings their AAA credit rating and their impactful guaranty
program. GSK, Merck and Pfizer are contributing both their capital and their product
development expertise ... Group, ImpactAssets, the GIIN;
• Anchor investors in the Global Health Investment Fund, such as GSK, Pfizer, Merck,
KfW, IFC, Grand Challenges Canada and the Children's Investment Fund Foundation;
• High
https://www.justice.gov/epstein/files/DataSet%209/EFTA01103797.pdf